Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
Status unknown · Phase 2 · NCT02968303
Conditions: Melanoma, Malignant, of Soft Parts
At a glance
- Research payments reported, 2025
- $2.8M
- U.S. investigators named
- 32
- Sites paid
- 36
- Planned or actual enrollment
- 200
About the trial
- Sponsor
- Radboud University Medical Center (with The Netherlands Cancer Institute, Isala)
- Tested
- Vemurafenib and Cobimetinib (drug)
- Dates
- Started 2017-01-27; completion 2023-10
- Results posted
- Not yet
Rationale: The combination of ipilimumab and nivolumab induces relatively high response rates and promising response depth in late stage melanoma. Nevertheless, it takes time till responses occur and still a significant number of patients do not benefit from treatment, due to rapid progressive disease or resistance to therapy. In contrast to immunotherapies targeted therapies (BRAF or MEK inhibitors), can induce faster and higher response rates, but often of shorter duration, even when combined. Initial attempts of combining vemurafenib or dabrafenib + trametinib with ipilimumab failed due to toxicity. Patients with elevated levels of serum LDH are less likely to respond to immunotherapy …
From ClinicalTrials.gov, last updated 2020-06-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.8M in research payments for this study in 2025 (66 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anita Kohli, MD Infectious Disease · Chandler, AZ
- Yessica R. Sachdeva, M.D. Internal Medicine · Mesa, AZ
- Mark P. Christiansen, MD Endocrinology & Diabetes · Walnut Creek, CA
- Stanley Hsia, M.D. Endocrinology & Diabetes · Los Angeles, CA
- Lawrence D. Sher, M.D. Pediatrics · Rolling Hills Estates, CA
- Cathy B. Barnes, MD Family Medicine · New Port Richey, FL
- Edgardo J. Riverarivera, MD Emergency Medicine · Leesburg, FL
- Senan Sultan, M.D. Endocrinology & Diabetes · Jacksonville, FL
- Alan Parsa, M.D. Endocrinology & Diabetes · Honolulu, HI
- Manish Jain, M.D. Rheumatology · Chicago, IL
- Susan R. Brian, MD Endocrinology & Diabetes · Topeka, KS
- Harold E. Bays, MD Endocrinology & Diabetes · Louisville, KY
- James P. Maynard, M.D. Neurology · Fort Thomas, KY
- Angela K. Fitch, MD Obesity Medicine · Boston, MA
- Jeffrey A. Norton, M.D. Pain Medicine · Lawrence, MA
- Timothy R. Smith, M.D. Internal Medicine · Saint Peters, MO
- Rupal Trivedi, MD Family Medicine · Saint Louis, MO
- Claire Presswood Internal Medicine · Morehead City, NC
- Cornell V. Calinescu, MD Emergency Medicine · Las Vegas, NV
- Laszlo L. Mechtler, MD Neurology · Amherst, NY
- Warren D. Spinner, D.O. Neurology · Port Jefferson Station, NY
- Agam Bansal, MD Internal Medicine · Cleveland, OH
- Felix O. Berglund, MD Cardiology · Nashville, TN
- Saras Sharma, D.O. Gastroenterology · Nashville, TN
- Amer Al-karadsheh, M.D. Endocrinology & Diabetes · Houston, TX
- Nomita J. Kim, MD Family Medicine · Austin, TX
- Jara K. Mcdonald, M.D. Family Medicine · Marble Falls, TX
- Julio Rosenstock, M.D. Endocrinology & Diabetes · Dallas, TX
- Brandon Lawrence, M.D. Orthopedic Surgery · Salt Lake City, UT
- Stephan H. Jannach, MD Family Medicine · Danville, VA
- Kathryn H. Eren, M.D. Family Medicine · Wenatchee, WA
- Anton Grasch, MD Family Medicine · Wenatchee, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Great Lakes Clinical Trials $289,505
- Headlands Horizons LLC $244,274
- Charter Research LLC $236,456
- Las Vegas Medical Research LLC $232,771
- Peninsula Headlands LLC $220,152
- Endocrine Ips PLLC $207,973
- Lucas Research Inc $174,049
- Institute for Liver Health LLC $156,937
- Suncoast Clinical Research $142,618
- Sociedad Espanola De Medicina De La Adolescencia $135,416
- Studymetrix Research LLC $121,054
- Cotton Oneil Msd of Stormont Vail Healthcare $104,320
- Pacific Diabetes and Endocrine Center $101,082
- Danville Orthopedic Clinic Inc $80,530
- True North Med at N Suffolk Pplc $77,883
- Ascension Medical Group $57,751
- Seen Medical of Ma PC DBA Knownwell $55,718
- Central Washington Health Services $41,008
- Cti Holdings Inc DBA Community Research Management Associates Inc $30,992
- Dent Neurosciences Research Center Inc $28,600
- Velocity Clinical Research Inc $27,545
- Palos Verdes Medical Group $6,511
- Tekton Research Inc $4,823
- Diabetes and Endocrinology Consultants $3,495
- North Suffolk Neurology $3,353
- Wenatchee Valley Hospital $2,406
- Northeast Research Institute $2,236
- Ima Evaluations LLC DBA Ima Clinical Research $2,200
- University at Buffalo $2,199
- Knownwell $2,036
- Medex Healthcare Research Inc $1,912
- Louisville Metabolic $1,861
- Dallas Diabetes and Endo Research Center PA $645
- Andrew J Lewin Med DBA National Rsrch Institute $440
- Cahaba Research $130
- Cleveland Clinic, OH $99
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.